Literature DB >> 22836806

Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis.

Elena Campello1, Luca Spiezia, Claudia M Radu, Maria Bon, Sabrina Gavasso, Patrizia Zerbinati, Barry Woodhams, Daniela Tormene, Paolo Prandoni, Paolo Simioni.   

Abstract

Although factor V Leiden (FVL) is a major determinant of thrombotic risk, the reason why less than 10% of carriers eventually develop venous thromboembolic (VTE) events is unknown. Recent observations suggest that circulating levels of microparticles (MP) may contribute to the thrombogenic profile of FVL carriers. We measured the plasma level of annexin V-MP (AMP) platelet-MP (PMP), endothelial-MP (EMP), leukocyte-MP (LMP) and tissue factor-bearing MP (TF(+)MP), and the MP procoagulant activity (PPL) in 142 carriers of FVL (of these 30 homozygous and 49 with prior VTE), and in 142 age and gender-matched healthy individuals. The mean (± SD) level of AMP was 2,802 ± 853 MP/μl in carriers and 1,682 ± 897 in controls (p<0.0001). A statistically significant difference between homozygous and heterozygous carriers of FVL was seen in the level of PMP, EMP and LMP, but not in that of the remaining parameters. When the analysis was confined to carriers with and without a VTE history, the mean level of AMP was 3,110 ± 791 MP/μl in the former, and 2,615 ± 839 MP/μl in the latter (p<0.005). The mean level of all subtypes of circulating MP showed a similar pattern. The PPL clotting time was 39 ± 9 seconds (sec) in carriers, and 52 ± 15 sec in controls (p=0.003); and was 35 ± 8 sec in carriers with prior thrombosis, and 41 ± 10 sec in thrombosis-free carriers (p<0.005). Our study results suggest that circulating MP may contribute to the development of thrombosis in carriers of FVL mutation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22836806     DOI: 10.1160/TH12-05-0280

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

Review 1.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

2.  Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia.

Authors:  Marina Marchetti; Carmen J Tartari; Laura Russo; Marina Panova-Noeva; Annamaria Leuzzi; Alessandro Rambaldi; Guido Finazzi; Barry Woodhams; Anna Falanga
Journal:  Am J Hematol       Date:  2013-11-20       Impact factor: 10.047

3.  Frequency of Leiden Mutation in Newborns with Birth Weight below 1500 g.

Authors:  Jiri Dusek; Lenka Nedvedova; Ondrej Scheinost; Milan Hanzl; Eva Kantorova; Eva Fendrstatova; Radim J Sram; Hana Kotouckova; Jan Voracek
Journal:  Healthcare (Basel)       Date:  2022-05-06

Review 4.  Endothelial microvesicles in hypoxic hypoxia diseases.

Authors:  Fan Deng; Shuang Wang; Riping Xu; Wenqian Yu; Xianyu Wang; Liangqing Zhang
Journal:  J Cell Mol Med       Date:  2018-05-29       Impact factor: 5.295

5.  Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.

Authors:  Elena Campello; Luca Spiezia; Chiara Simion; Daniela Tormene; Giuseppe Camporese; Fabio Dalla Valle; Anna Poretto; Cristiana Bulato; Sabrina Gavasso; Claudia Maria Radu; Paolo Simioni
Journal:  J Am Heart Assoc       Date:  2020-11-23       Impact factor: 5.501

6.  Plasma procoagulant phospholipid clotting time and venous thromboembolism risk.

Authors:  Cathrine Ramberg; Line Wilsgård; Nadezhda Latysheva; Sigrid K Brækkan; Kristian Hindberg; Timofey Sovershaev; Omri Snir; John-Bjarne Hansen
Journal:  Res Pract Thromb Haemost       Date:  2021-12-20

Review 7.  Extracellular Vesicles Linking Inflammation, Cancer and Thrombotic Risks.

Authors:  Sarah Beck; Bernhard Hochreiter; Johannes A Schmid
Journal:  Front Cell Dev Biol       Date:  2022-03-17

8.  Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19.

Authors:  Elena Campello; Claudia Maria Radu; Chiara Simion; Luca Spiezia; Cristiana Bulato; Sabrina Gavasso; Daniela Tormene; Nicola Perin; Giacomo Turatti; Paolo Simioni
Journal:  Front Cell Dev Biol       Date:  2022-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.